GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2007

BioWa Licenses Antibody Platform to Takeda

  • Takeda Pharmaceutical has gained access to BioWa’s Potelligent® Technology platform for the development of antibody-dependent cellular cytotoxicity-enhanced (ADCC) antibodies.

    The agreement grants Takeda nonexclusive rights to research, develop, manufacture, and commercialize antibodies based on this tool for an undisclosed number of targets. In return, BioWa will receive an upfront payment, license fees, development milestones, and royalties.

    Potelligent Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, according to BioWa. Potelligent Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Cancer Drug Approvals and Efficacy

Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?

More »